SEC Form 4 · accession 0001209191-19-001612
SELLAS Life Sciences Group, Inc. · SLS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Angelos M. Stergiou
Officer — President and CEO · Director
Period of report
Dec 31, 2018
Accepted (ET)
Jan 3, 2019 · 9:03 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001390478
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Dec 31, 2018 | S | 23,277 | $1.254 | D | 426,858 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The Reporting Person sold such shares to cover personal income tax liability.
- F2The price reported is a weighted average price. The shares were sold at prices ranging from $1.23 to $1.31 The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.